Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rhiannon Maudsley

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical and Translational Science|January 21, 2026
Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal WomenAndy Sykes, Helena Engman, Nigel Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast CancerJohn F R Robertson, Abigail Evans, Stephan Henschen, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast CancerLillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic CancersUdai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical and Translational Science|January 21, 2026
Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal WomenAndy Sykes, Helena Engman, Nigel Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast CancerJohn F R Robertson, Abigail Evans, Stephan Henschen, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast CancerLillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic CancersUdai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
Pageof 1